Table 2 Ongoing CAR-T cell therapy trials for hematologic malignancies
From: Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Clinical Study | Study Type | Indication | Target Antigen | Status | Sponsor |
|---|---|---|---|---|---|
NCT04340154 | Phase II | ALL | CD19 and CD22 | Recruiting | Beijing Boren Hospital |
NCT05727683 | Phase I | R/R B-ALL | CD19 | Recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. |
NCT05381662 | phase I/II | ALL | CD19 | Recruiting | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
NCT04840875 | Phase I | Acute T-cell leukemia / lymphoma | CD7 | Recruiting | Beijing Boren Hospital |
NCT04340167 | phase II | R/R B-ALL | CD22 | Recruiting | Beijing Boren Hospital |
NCT04778579 | phase II | R/R B-ALL | CD19 | Recruiting | Institut d’Investigacions Biomèdiques August Pi i Sunyer (Responsible Party) |
NCT05149391 | Phase 1 | B Cell NHL | CD19 and CD20 | Recruiting | Peking University Cancer Hospital & Institute |
NCT05312476 | phase II | R/ B-cell NHL | Igβ | Recruiting | The First Affiliated Hospital of Soochow University |
NCT05260957 | phase II | Aggressive NHL R/R NHL | CD19 | Recruiting | University of Miami |
NCT04089215 | phase II | R/R Â NHL | CD19 | Recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. |
NCT05420493 | Phase 1 | R/R NHL | CD19 | Recruiting | Chongqing Precision Biotech Co., Ltd |
NCT05757219 | phase II | DLBCL | CD19 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute |
NCT03758417 | phase II | MM | BCMA | Recruiting | Nanjing Legend Biotech Co. |
NCT05577000 | Phase 1 | R/R Â MM | BCMA | Recruiting | University of California, San Francisco |
NCT04155749 | Phase 1 | R/R MM | BCMA | Recruiting | Arcellx, Inc. |
NCT03943472 | Early Phase 1 | R/R MM | BCMA | Recruiting | Hrain Biotechnology Co., Ltd. |
NCT04272151 | Phase I/​II | R/R MM | BCMA | Recruiting | Chongqing Precision Biotech Co., Ltd |
NCT05457010 | Phase 1 | AML, MDS | sparX | Recruiting | Arcellx, Inc. |
NCT04219163 | Phase 1 | R/R AML | CLL-1 | Recruiting | Baylor College of Medicine |
NCT04835519 | Phase I/​II | R/R AML | CD33 | Recruiting | Beijing Boren Hospital |
NCT04803929 | Early Phase 1 | R/​R AML(M4/​M5) | ILT3 | Recruiting | Carbiogene Therapeutics Co. Ltd. |
NCT05023707 | Phase I/​II | AML | FLT3 | Recruiting | The First Affiliated Hospital of Soochow University |
NCT05488132 | Phase I/​II | AML | siglec-6 | Recruiting | Xuzhou Medical University |
NCT04351022 | Phase I/​II | AML | CD38 | Recruiting | The First Affiliated Hospital of Soochow University |
NCT05266950 | Phase 1 | R/​R  AML | CI-135 | Recruiting | Beijing Boren Hospital |